Win Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Win Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-586	Closed	-$168K	–	164
2022 Q2	$168K	Buy	+586	New	+$157K	0.33%	19

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Win Advisors's VRTX Position: Q3 2022 in Review

Win Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q3 2022, closing a stake of 586 shares — an estimated $168K sold.

Win Advisors first reported a position in VRTX in Q2 2022 and held it in 1 quarter. The position peaked at $168K in Q2 2022. 1,124 funds tracked by Wall St. Rank hold VRTX as of Q3 2022.

Win Advisors reported no remaining Vertex Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Win Advisors sold 586 Vertex Pharmaceuticals shares in Q3 2022, an estimated $168K.
Win Advisors first reported a position in Vertex Pharmaceuticals in Q2 2022 and held it in 1 quarter.
Win Advisors's Vertex Pharmaceuticals position peaked at $168K in Q2 2022.
1,124 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2022.

Based on Win Advisors's 13F filing for Q3 2022, filed 27 Oct 2022.